Discover and read the best of Twitter Threads about #Microalbuminuria
Most recents (4)
1) Welcome to a 🆕accredited tweetorial from @cardiomet_CE! We welcome back expert faculty @ChristosArgyrop to discuss screening for #CKD in pts w/ #T2D & the role of routine assessment for #microalbuminuria as an effective diagnostic, risk stratification, & patient ed tool.
2) Christos Argyropoulos MD, PhD @ChristosArgyrop is Division Chief, Nephrology @UNMHSC. #CKD is chronic #kidneydisease, #ESKD is end-stage kidney disease.
#FOAMed #nephtwitter #cardiotwitter @MedTweetorials @NephUCommunity @ISNkidneycare @KidneyDiseaseFm
#FOAMed #nephtwitter #cardiotwitter @MedTweetorials @NephUCommunity @ISNkidneycare @KidneyDiseaseFm
3) This program is intended for #HCPs and is supported by an unrestricted educational grant from Bayer. Statement of accreditation & faculty disclosures at cardiometabolic-ce.com/disclosures/.
FOLLOW US for more expert-authored #tweetorials and earn #MedEd
FOLLOW US for more expert-authored #tweetorials and earn #MedEd
Join us tomorrow for the launch of a new #accredited #tweetorial on the primary care management of #hyperlipidemia covering the relationship between #LDL_C & major #CV events, CV risk categories, recommended LDL-C treatment goals, & oral therapeutic options for lipid-lowering
1) Welcome to a new #tweetorial on the primary care management of #hyperlipidemia. Our returning @cardiomet_CE expert author is dedicated #SoMe education advocate Kevin Fernando, FRCGP FRCP Edin, FAcadMEd MSc Diabetes @drkevinfernando
2a) This is the next instalment of @cardiomet_CE's 10-part #tweetorial foundational series on #lipid management! It is accredited for #CME/CE and intended for #physicians #physicianassociates #nurses #nursepractitioners #pharmacists.
#FOAMed @MedTweetorials #cardiotwitter
#FOAMed @MedTweetorials #cardiotwitter
1) Welcome to a new #accredited #tweetorial on Clinical and Laboratory Manifestations of #DKD in #T2D: From Early Identification to Monitoring Management. Your expert author is @edgarvlermamd.
2a) This activity is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers. It is accredited for #physicians #physicianassistants #nurses #NPs #pharmacists. Check out @cardiomet_ce for more🆓CE/#CME.
2b) Past programs are still eligible for credit & can be found at cardiometabolic-ce.com. Faculty disclosures are at cardiometabolic-ce.com/disclosures/.
#FOAMed #medtwitter #diabetesmanagement #kidneydisease #diabetickidneydisease #diabetes @goKDIGO @MedTweetorials @nephondemand
#FOAMed #medtwitter #diabetesmanagement #kidneydisease #diabetickidneydisease #diabetes @goKDIGO @MedTweetorials @nephondemand
(1) Welcome to this #accredited #tweetorial, on recent & emerging data on finerenone, a non-steroidal mineralocorticoid receptor antagonist. We’ll discuss what it is, what evidence supports its use, & where it might fit into future #renal guidelines. I am @drkevinfernando.
(2) This program is supported by an educational grant from Bayer and is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com.
(3) Let's start with a knowledge check.
The following therapeutic options have demonstrated a significant reduction in the progression of both #CKD and #cardiovascular mortality in people living with #T2D:
1. ACEi's & ARBs
2. Spironolactone
3. SGLT2 inhibitors
4. Finerenone
The following therapeutic options have demonstrated a significant reduction in the progression of both #CKD and #cardiovascular mortality in people living with #T2D:
1. ACEi's & ARBs
2. Spironolactone
3. SGLT2 inhibitors
4. Finerenone
